Two US-developed treatments for breast cancer and a degenerative eye disease are set to undergo large-scale clinical trials across the Greater Bay Area. The initiative is the result of a collaborative agreement involving Hong Kong, Shenzhen, and a pharmaceutical start-up founded by a former lawmaker.
The project highlights cross-border cooperation in the region to advance medical research and drug development. By utilizing facilities and resources across multiple jurisdictions within the Greater Bay Area, the partners aim to facilitate the testing and potential future availability of these novel therapies.
In-depth summary · AI, neutral